Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Eisai Research Institute

Norimasa Miyamoto

Takayuki Hida

Hiroyuki Yoshimura

Shigeki Hibi

Mitsuo Nagai

Ieharu Hishinuma

Junichi Nagakawa

Makoto Asada

Aichi Ogasawara

Shinya Abe

Katsuya Tagami

Takashi Yamanaka

Kouichi Kikuchi

Seiko Higashi

Kenji Tai

Hirokazu Tanaka

Tomoko Sekiya

Naoko Massaki

Isao Yamatsu

Koichi Kikuchi

Yuichi Ono

Takeshi Nagasu

Nozomu Koyanagi

Kentaro Yoshimatsu

Hiroshi Yoshino

Yoichi Ozawa

Kohei Sawada

Takashi Owa

Mitsuhiro Ino

Isao Tanaka

Naoko Hata

Takashi Yoshinaga

Kyosuke Kito

Tatsuo Okauchi

Yukio Nishizawa

Tetsuhiro Niidome

Shinji Hatakeyama

Toru Oki

Eiki Takahashi

Kenichi Morita

Yoshitoshi Kasuya

Kana Namiki

The present invention provides a neural stem cell having increased passage ability and a method for manufacturing a neural stem cell having increased passage ability. A neural stem cell in which the N-type calcium channel gene is knocked out or the influx of Ca2+ via the N-type calcium channel is substantially absent can be passaged for at least 4 generations and maintains the differentiation potential into a nerve cell even after passage for 4 generations.

Neural stem cell having increased passage ability, method for manufacturing neural stem cell having said increased passage abiility, and method for culturing neural stem cells for increasing passage ability of neural stem cells

The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.

Method for screening of substance which alter GPR120-mediated cell-stimulating activities

The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.

Method of screening substance useful in treating disease with the use of GPR40 and phospholipase

A non-human animal in which a gene coding for the N-type calcium channel is disrupted to lack functional N-type calcium channel, and a method for screening for a substance having a pharmacological action on blood pressure control, transmission of pain, blood sugar level control and so forth by using the animal.

N-calcium channel knockout animal

An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I):

Appetite-stimulating agents and remedies for anorexia

Mono- or polyenic carboxylic acid derivatives

To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:

Compounds of the formula and compounds of the formula ##STR1## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Mono-or polyenic carboxylic acid derivatives

Heterocycle-containing carbonic acid derivatives

Growing community of inventors

Tsukuba, Japan

Norimasa Miyamoto